Atea Pharmaceuticals Completes Enrollment Of Over 880 Treatment-naïve Patients In C-BEYOND Phase 3 Trial Of Fixed-dose Combination Bemnifosbuvir And Ruzasvir Compared To Sofosbuvir And Velpatasvir Regime For Hepatitis C Virus; Results Are Expected Mid-year 2026

In addition to C-BEYOND, Atea continues to advance enrollment of treatment-naïve patients in C-FORWARD, a Phase 3 trial evaluating this same FDC regimen in 880 patients at approximately 120 clinical trial sites in up to 17 countries outside of North America. Completion of enrollment in C-FORWARD is expected mid-year 2026, with Phase 3 topline results anticipated year-end 2026. In both studies, the FDC regimen of bemnifosbuvir and ruzasvir is administered orally once-daily for 8 weeks (in patients without cirrhosis) or 12 weeks (in patients with compensated cirrhosis) while the comparator FDC regimen of sofosbuvir and velpatasvir is administered orally once-daily for 12 weeks.